Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.68 -1.9%	$3.91	$2.90 ▼ $11.16	$338.02M	0.18	2.92 million shs	1.60 million shs
CADL Candel Therapeutics	$5.11 -12.8%	$5.99	$3.79 ▼ $14.60	$317.84M	-0.9	564,478 shs	2.40 million shs
JMAC Maxpro Capital Acquisition	$4.21 +7.1%	$5.88	$7.50 ▼ $19.22	$56.53M	0.01	74,040 shs	11,817 shs
LRMR Larimar Therapeutics	$3.94 +6.2%	$3.54	$1.61 ▼ $9.50	$299.66M	0.91	1.63 million shs	1.51 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	-2.09%	+9.01%	+3.88%	-31.69%	-44.03%
CADL Candel Therapeutics	+1.21%	-1.68%	-6.84%	+4.64%	-13.19%
JMAC Maxpro Capital Acquisition	0.00%	-37.89%	-33.02%	-39.97%	-63.63%
LRMR Larimar Therapeutics	+2.49%	-4.13%	+7.85%	+51.43%	-53.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	2.9714 of 5 stars	4.3	2.0	0.0	0.0	1.8	1.7	0.6
CADL Candel Therapeutics	2.1039 of 5 stars	3.5	1.0	0.0	0.0	2.2	1.7	0.6
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	3.1364 of 5 stars	3.6	3.0	0.0	0.0	3.2	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.57	Moderate Buy	$17.40	372.83% Upside
CADL Candel Therapeutics	3.00	Buy	$20.00	291.39% Upside
JMAC Maxpro Capital Acquisition	0.00	N/A	N/A	N/A
LRMR Larimar Therapeutics	3.10	Buy	$18.43	367.73% Upside

Current Analyst Ratings Breakdown

Latest JMAC, LRMR, CADL, and ALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2025	CADL Candel Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$13.00 ➝ $7.00
8/15/2025	LRMR Larimar Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$22.00 ➝ $18.00
8/13/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
8/13/2025	ALT Altimmune	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $24.00
8/13/2025	ALT Altimmune	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $18.00
7/10/2025	ALT Altimmune	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
7/10/2025	ALT Altimmune	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$25.00 ➝ $15.00
7/9/2025	CADL Candel Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/30/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$23.00
6/27/2025	ALT Altimmune	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/27/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00

(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$20K	16,239.84	N/A	N/A	$1.83 per share	2.01
CADL Candel Therapeutics	$120K	2,337.83	N/A	N/A	$1.64 per share	3.12
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$1.45 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$95.06M	-$1.18	N/A	N/A	N/A	-438,730.03%	-62.63%	-55.29%	11/11/2025 (Estimated)
CADL Candel Therapeutics	-$55.18M	-$0.69	N/A	N/A	N/A	N/A	-41.00%	-26.81%	11/13/2025 (Estimated)
JMAC Maxpro Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	-$80.60M	-$1.56	N/A	N/A	N/A	N/A	-62.92%	-53.98%	10/29/2025 (Estimated)

Latest JMAC, LRMR, CADL, and ALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CADL Candel Therapeutics	-$0.17	-$0.09	+$0.08	-$0.09	N/A	N/A
8/14/2025	Q2 2025	LRMR Larimar Therapeutics	-$0.47	-$0.41	+$0.06	-$0.41	N/A	N/A
8/12/2025	Q2 2025	ALT Altimmune	-$0.32	-$0.27	+$0.05	-$0.27	$0.00 million	$0.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	0.09	20.44	20.44
CADL Candel Therapeutics	0.01	7.04	7.04
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	5.46	5.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
CADL Candel Therapeutics	13.93%
JMAC Maxpro Capital Acquisition	73.18%
LRMR Larimar Therapeutics	91.92%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.40%
CADL Candel Therapeutics	16.60%
JMAC Maxpro Capital Acquisition	19.27%
LRMR Larimar Therapeutics	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	88.26 million	84.37 million	Optionable
CADL Candel Therapeutics	60	54.90 million	45.78 million	Optionable
JMAC Maxpro Capital Acquisition	2,021	13.43 million	10.84 million	Not Optionable
LRMR Larimar Therapeutics	30	82.78 million	79.05 million	Optionable

JMAC, LRMR, CADL, and ALT Headlines

Recent News About These Companies

Driehaus Capital Management LLC Decreases Stock Holdings in Larimar Therapeutics, Inc. $LRMR

September 3 at 5:25 AM | marketbeat.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives $18.43 Average Target Price from Analysts

August 23, 2025 | americanbankingnews.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Buy" from Analysts

August 21, 2025 | marketbeat.com

Q4 Earnings Estimate for LRMR Issued By Leerink Partnrs

August 20, 2025 | marketbeat.com

Q3 EPS Forecast for Larimar Therapeutics Lifted by Analyst

August 19, 2025 | marketbeat.com

William Blair Analysts Lift Earnings Estimates for LRMR

August 19, 2025 | marketbeat.com

Larimar Therapeutics (NASDAQ:LRMR) Issues Earnings Results

August 17, 2025 | marketbeat.com

Research Analysts Set Expectations for LRMR FY2028 Earnings

August 17, 2025 | marketbeat.com

Larimar Therapeutics (NASDAQ:LRMR) Price Target Cut to $18.00 by Analysts at JMP Securities

August 17, 2025 | marketbeat.com

Leerink Partners Keeps Their Buy Rating on Larimar Therapeutics (LRMR)

August 16, 2025 | theglobeandmail.com

Larimar Therapeutics (LRMR) Gets a Buy from Truist Financial

August 16, 2025 | theglobeandmail.com

Larimar Therapeutics Advances Nomlabofusp Program Toward 2026 FDA Filing

August 16, 2025 | msn.com

3 Best Stocks to Buy Now, 8/15/2025, According to Top Analysts

August 15, 2025 | msn.com

Larimar Therapeutics Announces $64.4 Million Stock Offering

August 15, 2025 | theglobeandmail.com

Larimar Therapeutics price target lowered to $18 from $22 at Citizens JMP

August 15, 2025 | msn.com

Larimar Therapeutics Advances Nomlabofusp Program Amid Financial Losses

August 14, 2025 | tipranks.com

Larimar Beats Q2 Loss Estimates

August 14, 2025 | aol.comA

Larimar Therapeutics reports Q2 EPS (41c), consensus (49c)

August 14, 2025 | msn.com

Larimar Therapeutics Reports Q2 2025 Financial Results

August 14, 2025 | msn.com

Altium Capital Management LLC Reduces Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR)

August 14, 2025 | marketbeat.com

Larimar Therapeutics Reports Second Quarter 2025 Financial Results

August 14, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

JMAC, LRMR, CADL, and ALT Company Descriptions

Altimmune NASDAQ:ALT

$3.68 -0.07 (-1.87%)

Closing price 04:00 PM Eastern

Extended Trading

$3.70 +0.01 (+0.41%)

As of 07:06 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Candel Therapeutics NASDAQ:CADL

$5.11 -0.75 (-12.80%)

Closing price 04:00 PM Eastern

Extended Trading

$5.14 +0.03 (+0.59%)

As of 07:59 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Maxpro Capital Acquisition NASDAQ:JMAC

$4.21 +0.28 (+7.08%)

As of 09/2/2025

Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.

Larimar Therapeutics NASDAQ:LRMR

$3.94 +0.23 (+6.20%)

Closing price 04:00 PM Eastern

Extended Trading

$3.93 -0.01 (-0.25%)

As of 08:00 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time